Bildkälla: Stockfoto

IRLAB: FDA meeting closing in - Redeye

Redeye updates its view of IRLAB following the Q4 report and largely reiterate our previous view. We think that the next significant trigger is the outcome of the end-of-phase II meeting on Mesdopetam, news on business development/financing and trial initiation of the IRL757 phase I trial.

Redeye updates its view of IRLAB following the Q4 report and largely reiterate our previous view. We think that the next significant trigger is the outcome of the end-of-phase II meeting on Mesdopetam, news on business development/financing and trial initiation of the IRL757 phase I trial.
Börsvärldens nyhetsbrev
ANNONSER